Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.63 |
| ▸ | PIK3R2 | O00459 | 6/20 | 0.63 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993155 | 1.00 | PIK3CD (0.66) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL1988283 | 1.00 | PIK3CD (0.66) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL15303057 | 0.89 | PIK3CD (0.82) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL15303056 | 0.89 | PIK3CD (0.82) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL1989093 | 0.88 | PIK3CD (0.64) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL1994376 | 0.88 | PIK3CD (0.64) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL1994856 | 0.88 | PIK3CD (0.64) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL15307360 | 0.84 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL19344371 | 0.83 | PIK3CD (0.82) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB | |
| SCHEMBL15302960 | 0.83 | PIK3CD (0.82) | PIK3CDPIK3CGPIK3R2PIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633313-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2513109-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075628-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152296-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885PIK3CG 54/4885PIK3R2 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.